|Bid||0.1226 x 8800|
|Ask||0.1227 x 8300|
|Day's Range||0.1200 - 0.1449|
|52 Week Range||0.1000 - 2.1200|
|PE Ratio (TTM)||0.48|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.88|
Neovasc Inc (NASDAQ:NVCN) trades with a trailing P/E of 0.5x, which is lower than the industry average of 33.6x. Although some investors may jump to the conclusion that this isRead More...
NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
Company management and large investors tend to have unparalleled views into the operations of their own company compared to a typical individual investor. When these insiders buy, their stock tendsRead More...
VANCOUVER, Feb. 12, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th at 2:30 pm ET at the Lotte New York Palace in New York City. A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com.
Neovasc Announces Receipt of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina
VANCOUVER, Feb. 1, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies, today announced that the "Institut für das Entgeltsystem im Krankenhaus" ("InEk"), the German Institute for the Hospital Remuneration System, has awarded its Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB status 1 designation for 2018. InEK, is responsible for prioritizing new therapies in Germany through the NUB process. Yesterday, InEK upgraded the status of the Neovasc Reducer from status 4 to status 1 - the highest priority designation available.
"Neovasc has reached an important turning point, and, as such, we have conducted a search for a leader with the experience and skill set to build on the progress made by Alexei Marko during his tenure as CEO," said Paul Geyer, chairman of Neovasc.
VANCOUVER, Jan. 18, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (Nasdaq, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") was featured in a "live case" broadcast to more than 800 participants at the Kardiologie Symposium 2018 held in Berlin, Germany. The successful live case was performed by Dr. Spyrantis and Professor Banai in the Sana-Klinikum Lichtenberg. "The patient in this case, like a growing number of patients, still had significant angina after all medical treatment options had been exhausted. There is clearly a need to address this patient population as their quality of life is very poor and the burden on the healthcare system is significant due to the frequency of emergency room visits," commented Dr. Olaf Göing, a panelist during the live case session.
VANCOUVER, Jan. 8, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today provided an update on its clinical program for the Tiara™ ("Tiara") valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death. In total, 47 patients have now been implanted with Tiara, 12 of which are enrolled in the Company's CE Mark trial, TIARA-II. Of note, 10 patients have been treated in the last two months, including 4 already in 2018. This momentum is expected to continue as the Company expands both the number of centres and its clinical support teams.
VANCOUVER, Jan. 2, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX:NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
VANCOUVER, Dec. 6, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported its Neovasc Reducer™ ("Reducer") medical device was featured in a "live case" broadcast at the 2017 Innovations in Cardiovascular Interventions (ICI) conference held in Tel Aviv, Israel. In the live case broadcast to the conference from the Soroka University Medical Center in Beersheba Israel, Drs. Koifman and Bazan successfully implanted a Reducer in the coronary sinus of a patient suffering from very poor quality of life due to refractory angina pectoris, chest discomfort felt with even minimal effort, despite previous bypass surgery and multiple stent implantations. The live Reducer case was broadcast following a scientific presentation describing current available clinical data supporting the use of the Reducer as a safe and effective therapy for patients with refractory angina pectoris.
Categories: Yahoo FinanceGet free summary analysis Neovasc, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Neovasc, Inc. – Integra LifeSciences Holdings Corporation and ICU Medical, Inc. (IART-US and ICUI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.37 million, ... Read more (Read more...)
VANCOUVER, Nov. 27, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVC.TO) today announced that Chris Clark, chief financial officer, is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29th at 7:50 am ET at the Lotte New York Palace in New York City. A live audio webcast of the presentation will be available on the Investors page of Neovasc's website at www.neovasc.com. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the United States and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the United States, Canada and Europe.
Neovasc Closes Offering of Units Consisting of Common Shares and Warrants and Concurrent Private Placement of Notes and Warrants
VANCOUVER, Nov. 17, 2017 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the closing of its previously announced underwritten offering of 6,609,588 Series A units (the "Series A Units") and 19,066,780 Series B units (the "Series B Units" and together with the Series A Units, the "Units") of the Company, at a price of US$1.46 per Unit for gross proceeds of approximately US$37,487,497, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Neovasc (the "Offering"). Concurrent with the Offering, the Company completed a private placement for the sale of US$32,750,000 aggregate principal amount of senior secured convertible notes and Series E warrants of the Company for gross proceeds of US$27,837,500 (the "Concurrent Private Placement").
Neovasc Inc (TSX:NVCN), a healthcare equipment and supplies company based in Canada, saw significant share price volatility over the past couple of months on the TSX, rising to the highsRead More...
On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 6 cents. The medical device company posted revenue of $1.4 million in the period. The company's shares closed at ...
NASDAQ, TSX: NVCN VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ, TSX: NVCN) today announced financial results for the third quarter ...